Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine LearningCloud-based platform combines AI and machine learning to perform multivariate analysis, enabling real-time optimization of cell therapy performance and patient outcomes
Welcoming Victor Bornsztejn as Senior Vice President of CommercialSAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is pleased to announce the appointment of Victor Bornsztejn as the company’s new Senior Vice President of Commercial.
Culture Biosciences Appoints Chris Williams as Chief Executive OfficerFormer COO of Cytek Biosciences brings extensive bioprocessing experience to drive next phase of growth at Culture Biosciences
Culture Biosciences and Google Cloud Announce Collaboration to Revolutionize Bioprocess DevelopmentGemini AI integration with first upstream cloud-connected bioreactors will allow scientists in R&D bioprocess development to achieve optimal outcomes in less time.
Culture Biosciences Appoints Darcy Birse as Chief Commercial OfficerThe life science and biotech commercial veteran will lead the company's growth strategy
Biotech and Biopharma Executive Eliana Clark Joins Culture Biosciences’ Advisory BoardThe recently established group of senior industry leaders provides guidance as the company executes its growth strategy
Biotech Executive Beth Thompson-Webb Joins Culture Biosciences’ Board of DirectorsAccomplished industry leader will strengthen commercial expertise on Culture’s Board of Directors
Culture Biosciences and Cytiva team up to innovate in upstream bioprocessing to advance the development and manufacturing of new therapiesNew collaboration will provide both companies’ customers access to enhanced digital technologies for faster, more flexible, cost-effective, and more predictable scaling +++ When used in collaboration, the two companies’ technologies are expected to reduce process waste and costs for customers' target molecule milestones +++ Availability of Cytiva cell culture media and data analytics software to Culture Biosciences customers ensures they have greater support in experiments at scale
Culture Biosciences Focuses Technology and Service Platform on BiologicsIntelligent upstream bioprocess development for therapeutics using an integrated platform of cloud-based software, single-use bioreactors, simulation tools, and process development services. New leadership team members enhance company expertise in the biotech and biopharma industries
Culture Biosciences Raises $80M Series B to Tackle Demand for Large-Scale Biomanufacturing
Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million led by Northpond Ventures. Synthesis Capital also participated in the round. Existing investors Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, Box Group, Verily Life Sciences, and Section 32 also contributed. Andrew Lee, Ph.D., of Northpond Ventures will join Culture’s Board of Directors.
